Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.
García-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Pérez-Ramos M, Álvarez-Abril B, Ivars Rubio A, García-Garre E, Ayala de la Peña F, García-Martínez E. García-Torralba E, et al. Among authors: de la morena barrio p. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. Front Oncol. 2023. PMID: 37313470 Free PMC article.
A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge.
Vicente Conesa MA, Zafra Poves M, Carmona-Bayonas A, Ballester Navarro I, de la Morena Barrio P, Ivars Rubio A, Montenegro Luis S, García Garre E, Vicente V, Ayala de la Peña F. Vicente Conesa MA, et al. Among authors: de la morena barrio p. ESMO Open. 2022 Feb;7(1):100384. doi: 10.1016/j.esmoop.2022.100384. Epub 2022 Feb 7. ESMO Open. 2022. PMID: 35144121 Free PMC article.
Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer.
García-Torralba E, Pérez Ramos M, Ivars Rubio A, Navarro-Manzano E, Blaya Boluda N, de la Morena Barrio P, García-Garre E, Martínez Díaz F, Chaves-Benito A, García-Martínez E, Ayala de la Peña F. García-Torralba E, et al. Among authors: de la morena barrio p. Cancers (Basel). 2023 May 20;15(10):2846. doi: 10.3390/cancers15102846. Cancers (Basel). 2023. PMID: 37345183 Free PMC article.
Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).
Antolín Novoa S, Escrivá-de-Romaní S, Tolosa Ortega P, Oliva Fernández L, López López R, López González A, de la Morena Barrio P, Echavarria Díaz-Guardamino I, Alés Martinez JE, Garate Z, González-Cortijo L. Antolín Novoa S, et al. Among authors: de la morena barrio p. Cancer Treat Res Commun. 2023;37:100772. doi: 10.1016/j.ctarc.2023.100772. Epub 2023 Nov 1. Cancer Treat Res Commun. 2023. PMID: 37995519 Free article.
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
Garcia-Torralba E, Pérez Ramos M, Ivars Rubio A, Navarro Manzano E, Blaya Boluda N, Lloret Gil M, Aller A, de la Morena Barrio P, García Garre E, Martínez Díaz F, García Molina F, Chaves Benito A, García-Martínez E, Ayala de la Peña F. Garcia-Torralba E, et al. Among authors: de la morena barrio p. Breast Cancer Res Treat. 2024 Jun;205(3):475-485. doi: 10.1007/s10549-024-07286-x. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453782 Free PMC article.